Angiopoietin‐2 levels as a biomarker of cardiovascular risk in patients with hypertension

References

• Yusuf S., Reddy S., Ounpuu S., Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104: 2746–53
   PubMed Web of Science ®Google Scholar
• Kita Chun A., McGee S. R. Bedside diagnosis of coronary artery disease: a systematic review. Am J Med 2004; 117: 334–43
   Google Scholar
• Pope J. H., Aufderheide T. P., Ruthazer R., Woolard R. H., Feldman J. A., Beshansky J. R., et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342: 1163–70
   PubMed Web of Science ®Google Scholar
• MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J., et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–74
   PubMed Web of Science ®Google Scholar
• Collins R., Peto R., MacMahon S., Hebert P., Fiebach N. H., Eberlein K. A., et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short‐term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–38
   PubMed Web of Science ®Google Scholar
• McEwan P., Williams J. E., Griffiths J. D., Bagust A., Peters J. R., Hopkinson P., et al. Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med 2004; 21: 318–23
   PubMed Web of Science ®Google Scholar
• Vasan R. S. Biomarkers of Cardiovascular Disease: molecular basis and practical considerations. Circulation 2006; 11: 2335–62
   Google Scholar
• Moulton K. S. Plaque angiogenesis and atherosclerosis. Curr Atheroscler Rep 2001; 3: 225–33
   PubMedGoogle Scholar
• Le Noble F. A. C., Stassen F. R. M., Hacking W. J. G., Struijker Boudier H. A. J. Angiogenesis and hypertension. J Hypertens 1998; 16: 1563–72
   PubMed Web of Science ®Google Scholar
• Felmeden D. C., Blann A. D., Lip G. Y. H. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 2003; 24: 586–603
   PubMed Web of Science ®Google Scholar
• Patel J. V., Lim H. S., Nadar S., Tayebjee M., Hughes E. A., Lip G. Y. Abnormal soluble CD40 ligand and C‐reactive protein concentrations in hypertension: relationship to indices of angiogenesis. J Hypertens 2006; 24: 117–21
   PubMed Web of Science ®Google Scholar
• Felmeden D. C., Spencer C. G., Belgore F. M., Blann A. D., Beevers D. G., Lip G. Y. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003; 16: 11–20
   PubMed Web of Science ®Google Scholar
• Felmeden D. C., Spencer C. G. C., Chung N., Belgore F. M., Blann A. D., Beevers D. G., et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo‐Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol 2003; 92: 400–5
   PubMed Web of Science ®Google Scholar
• Nadar S. K., Blann A., Beevers D. G., Lip G. Y. Abnormal angiopoietins 1&2, angiopoietin receptor Tie‐2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub‐study of the Anglo‐Scandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med 2005; 258: 336–43
   PubMed Web of Science ®Google Scholar
• Lim H. S., Blann A. D., Chong A. Y., Freestone B., Lip G. Y. Plasma vascular endothelial growth factor, angiopoietin‐1, and angiopoietin‐2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004; 27: 2918–24
   PubMed Web of Science ®Google Scholar
• Chong A. Y., Caine G. J., Freestone B., Blann A. D., Lip G. Y. Plasma angiopoietin‐1, angiopoietin‐2, and angiopoietin receptor tie‐2 levels in congestive heart failure. J Am Coll Cardiol 2004; 43: 423–8
   PubMed Web of Science ®Google Scholar
• Lee K. W., Lip G. Y., Blann A. D. Plasma angiopoietin‐1, angiopoietin‐2, angiopoietin receptor tie‐2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004; 110: 2355–60
   PubMed Web of Science ®Google Scholar
• Stetler‐Stevenson W. G. Matrix metalloproteinases in angiogenesis: moving target for therapeutic intervention. J Clin Invest 1999; 103: 1237–41
   PubMed Web of Science ®Google Scholar
• Sever P. S., Dahlof B., Poulter N. R., Wedel H., Beevers G., Caulfield M., et al. ASCOT Steering Committee, Anglo‐Scandinavian Cardiac Outcomes Trial. Anglo‐Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol. J Hum Hypertens 2001; 15(Suppl 1)S11–2
   PubMedGoogle Scholar
• Kannel W. B., McGee D. L. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979; 241: 2035–8
   PubMed Web of Science ®Google Scholar
• Hanley A. J., Wagenknecht L. E., D'Agostino R. B., Zinman B., Haffner S. M. Identification of subjects with insulin resistance and beta‐cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 2003; 52: 2740–7
   PubMed Web of Science ®Google Scholar
• Lip P. L., Chatterjee S., Caine G. J., Hope‐Ross M., Gibson J., Blann A. D., et al. Plasma vascular endothelial growth factor, angiopoietin‐2, and soluble angiopoietin receptor tie‐2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Br J Ophthalmol 2004; 88: 1543–6
   PubMed Web of Science ®Google Scholar
• Jones N., Iljin K., Dumont D. J., Alitalo K. Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2001; 2: 257–67
   PubMed Web of Science ®Google Scholar
• Fiedler U., Scharpfenecker M., Koidl S., Hegen A., Grunow V., Schmidt J. M., et al. The Tie‐2 ligand angiopoietin‐2 is stored in and rapidly released upon stimulation from endothelial cell Weibel‐Palade bodies. Blood 2004; 103: 4150–6
   PubMed Web of Science ®Google Scholar
• Lim H. S., Lip G. Y., Blann A. D. Angiopoietin‐1 and angiopoietin‐2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 2005; 180: 113–8
   PubMed Web of Science ®Google Scholar
• Varughese G. I., Patel J. V., Tomson J., Blann A. D., Hughes E. A., Lip G. Y. Prognostic value of plasma soluble P‐selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high‐risk patients with hypertension: a sub‐study of the Anglo‐Scandinavian Cardiac Outcomes Trial. J Intern Med 2007; 261: 384–91
   PubMed Web of Science ®Google Scholar
• Sfiligoi C., De Luca A., Cascone I., Sorbello V., Fuso L., Ponzone R., et al. Angiopoietin‐2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer 2003; 103: 466–74
   PubMed Web of Science ®Google Scholar
• Tanaka F., Ishikawa S., Yanagihara K., Miyahara R., Kawano Y., Li M., et al. Expression of angiopoietins and its clinical significance in non‐small cell lung cancer. Cancer Res 2002; 62: 7124–9
   PubMed Web of Science ®Google Scholar